Some Caplyta Results in Schizophrenia Reach Print

4 Likes

“Although it remains unclear whether this potentially novel receptor-binding profile, particularly its serotonergic and glutamatergic activity, is clinically relevant, it raises the possibility that in addition to being a general treatment for schizophrenia, lumateperone may be helpful for a subset of treatment-resistant patients with schizophrenia,” Kantrowitz wrote.

4 Likes

Here’s what I noticed: “Lumateperone was also associated with reduced extrapyramidal symptoms…”.

3 Likes